Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus reuteri BGP-014
- Development stage
- Phase 2
- Lead developer
- BioGaia
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus reuteri BGP-014 is an investigational oral live biotherapeutic product (LBP) being developed by BioGaia Pharma AB for the treatment of mild to moderate active ulcerative colitis (UC). The active ingredient is a specific strain of the bacterium *Lactobacillus reuteri*, designated BGP-014, which is formulated into oral capsules. It is intended for use as an adjunctive therapy alongside standard treatments such as aminosalicylates or corticosteroids. The proposed mechanism of action involves the modulation of gut mucosal immunity, the reduction of pro-inflammatory cytokine production, and the restoration of intestinal barrier integrity. BGP-014 is currently undergoing Phase 1 clinical evaluation to assess its safety, tolerability, and exploratory efficacy in patients with active UC.
- Other names
- Lactobacillus reuteri BGP-014L. reuteri BGP-014
02
Targets
ADORA2A/ADORA2B (Adenosine A2A and A2B receptors)AHR (Aryl hydrocarbon receptor)HRH2 (Histamine H2 Receptor)PRR (Pattern recognition receptors)
Beyond the preview
Go deeper on lactobacillus reuteri BGP-014.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus reuteri BGP-014.